Piramal Pharma Limited has announced its Q1 FY27 results, showcasing a robust 17% year-on-year revenue growth, reaching ₹2,270 Crore. The company also achieved a significant 72% increase in EBITDA, with margins expanding by 400 basis points to 12.5%. This performance was driven by strong contributions from all three business segments: CDMO, CHG, and PCH, indicating broad-based growth and improved operational efficiency.
Piramal Pharma Reports Strong Q1 FY27 Performance
Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635) has announced its unaudited financial results for the first quarter (Q1) ended June 30, 2026. The company reported a healthy 17% year-on-year growth in revenue from operations, reaching ₹2,270 Crore compared to ₹1,934 Crore in Q1 FY26. This significant increase was driven by strong performances across all its business segments.
Key Financial Highlights
The consolidated financial highlights for Q1 FY27 reveal substantial improvements:
- Revenue from Operations: Increased by 17% to ₹2,270 Crore.
- EBITDA: Saw a remarkable surge of 72%, amounting to ₹285 Crore, up from ₹165 Crore in Q1 FY26.
- EBITDA Margin: Expanded by 400 basis points to 12.5% from 8.5% in the prior year quarter.
- Profit After Tax (after exceptional item): Reported a 15% increase, reaching ₹(69) Crore from ₹(82) Crore in Q1 FY26.
Segment-wise Performance
All three business segments contributed to the overall growth:
- CDMO (Contract Development and Manufacturing Organization): Revenue grew by 19% to ₹1,187 Crore.
- CHG (Complex Hospital Generics): Reported a 17% revenue increase to ₹743 Crore.
- PCH (Piramal Consumer Healthcare): Achieved 15% revenue growth, reaching ₹347 Crore.
Operational Excellence and Strategic Initiatives
Nandini Piramal, Chairperson, commented on the results, stating, “We have started FY27 on a strong note, with all three businesses delivering mid-to-high teens revenue growth alongside meaningful EBITDA margin expansion.” The company highlighted:
- Improved Operating Performance: Higher capacity utilization and operational excellence led to margin expansion.
- Quality Assurance: The Sellersville facility in the US received an Establishment Inspection Report from the US FDA, maintaining its Zero OAI status.
- CDMO Growth Drivers: Healthy pick-up in RFPs and order inflows, coupled with strong execution.
- CHG Market Leadership: Sustained leadership in US Sevoflurane and intrathecal Baclofen markets.
- PCH Momentum: Robust growth driven by Power Brands and e-commerce expansion.
Piramal Pharma Limited hosted an earnings conference call on July 30, 2026, to discuss these results with investors and analysts.
Source: BSE
